September 17, 2012 (BRONX, NY) The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, has awarded nearly $11 million to Albert Einstein College of Medicine of Yeshiva University to carry out a five-year multi-institutional study of hemoglobin toxicity that may complicate blood transfusions and reduce the effectiveness of blood substitutes. The long-term goals include making blood transfusions safer and more effective and better matching patients with the transfusion strategy best suited to them.
The research is especially important due to the explosion of obesity, diabetes and metabolic syndrome, which increases inflammation in blood vessels and can lead to transfusion complications.
The $10.8 million program project grant will be overseen by the principle investigator, Einstein's Joel Friedman, M.D., Ph.D. , who holds the Young Men's Division Chair in Physiology and is professor of physiology & biophysics and of medicine. The grant will fund research projects at Einstein, Rice University, the University of California, San Diego and the United States Food and Drug Administration (FDA), directed by Dr. Friedman, John Olson, Ph.D., Marcos Intaglietta, Ph.D., and Abdu Alayash, Ph.D., respectively.
The grant focuses on the study of hemoglobin, the protein that gives red blood cells their color. Red cells transport oxygen throughout the body and deliver it to cells. Hemoglobin normally stays inside red blood cells. But under some conditionsincluding sickle cell anemia and transfusions involving stored bloodred cells break open, or lyse, causing substantial amounts of hemoglobin to become acel
|Contact: Kim Newman |
Albert Einstein College of Medicine